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A. Establishment of the Prevention Program 
 
1. Legislation: Health Care Reform Law 2006.  In April 2006, the groundbreaking 
Massachusetts health care reform law (Chapter 58 of the Acts of 2006) directed the 
Massachusetts Department of Public Health (MDPH), Division of Health Care 
Quality (DHCQ) to develop a Statewide Infection Prevention and Control Program. 
The Betsy Lehman Center for Patient Safety and Medical Error Reduction (BLC) 
convened a panel of experts and key stakeholders.  This Expert Panel, with the 
assistance of a variety of local and national advisors, reviewed available evidence, 
made recommendations delineating the evidence-base strength of those 
recommendations, and developed specific proposals for prevention and reporting.  
Under the health care reform law a state budget line item was established to support 
the program. 
a.  Healthcare Associated Infection (HAI) Prevention Program 
Based on the recommendations of the Expert Panel, a collaborative of key 
components of the MDPH, including the DHCQ (the state regulatory and survey 
agent), the BLC and the Bureau of Infectious Diseases (BID), established the 
Healthcare-Associated Infection (HAI) Prevention and Control Program (HAI 
Program) in February 2008. 
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2. Legislation: Massachusetts Cost Containment, Transparency and Efficiency Act of 
2008 (Chapter 305 of the Acts of 2008).  This legislation also required reporting of 
HAIs (and other serious adverse events defined by the National Quality Forum) and 
the establishment of a comparative quality and cost information website, including 
data on HAIs and serious reportable events (SREs). 
a.  Health Care Quality and Cost Council (HCQCC) 
The HCQCC is charged with establishing statewide goals for improving health 
care quality, containing health care costs, and reducing racial and ethnic 
disparities in health care.  The MDPH Commissioner, John Auerbach, is a 
member of the HCQCC, and MDPH chairs several HCQCC committees that are 
developing and addressing the HAI and SRE prevention and reporting goals.  The 
HCQCC receives input and advice from an Advisory Committee that includes 
representation from consumers, business, labor, health care providers, and health 
plans.  Among the Council’s specific goals and strategies is the public reporting 
of HAIs and SREs. 
 
3. Expert Panel Recommendations and Best Practices 
a.  The Expert Panel endorsed a comprehensive set of recommendations 
encompassing HAI reporting and “best practices” for preventing HAIs, including 
programmatic aspects of hospital infection prevention and control programs. 
Technical specifications of these recommendations and a full description of the 
evidence-based process by which they were developed can be found in Part 1 of 
the full report --- Prevention and Control of Healthcare Associated Infection in 
Massachusetts, Part 1: Final Recommendations of the Expert Panel, January 31, 
2008.  Part 2 of the report contains the detailed information on several related 
projects that were undertaken.  These included: a statewide survey of acute care 
hospitals to determine their current activities and capacity for participating in 
additional HAI prevention and/or reporting efforts, focus groups with hospital 
executives concerning mandatory HAI reporting, formative research with the 
general public to determine appropriate formats for conveying HAI information, 
an economic analysis of HAI costs in Massachusetts, and a synopsis of literature 
concerning best practices for educating healthcare workers on prevention of 
HAIs.  The full report can be found at: www.mass.gov/dph/dhcq.  
 
4. Experience With Program Implementation and Reporting of Process and Outcome 
Measures 
a.  Workforce assessment 
Demands on infection prevention professionals in Massachusetts have increased, 
with significant time spent on a wide range of other activities including quality 
assurance, data management, staff education, occupational health, emergency 
preparedness and environmental issues.  In February 2007 there was an average of 
one infection preventionist (IP) full-time equivalent (FTE) per 178 hospital beds.  
Less than sixty percent of IPs stated that the resources for infection control 
activities in their hospital were adequate, even though the perceived rating of 
institutional support for infection control program activities was high. 
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1) Baseline data 
i Practices: - Infection prevention directors of 71 acute care hospitals 
were surveyed in February 2007 and 68 (96%) responded.  All of the 
hospitals were involved in the federally-required Centers for 
Medicare & Medicaid Services (CMS) programs, and many also 
participated in other multi-institution efforts to prevent HAIs, 
including the Institute for Healthcare Improvement (IHI) 100,000 
Lives Campaign, Leapfrog, and Patients First.  Prevention activities 
included strategies to reduce central line-associated bloodstream 
infections (CLABSIs), consistent and timely antibiotic prophylaxis 
for surgery, and isolation of patients who are positive for methicillin 
resistant Staphylococcus aureus (MRSA).  All hospitals were 
involved in efforts to improve hand hygiene adherence and decrease 
risk of infection through contact precautions.  Most hospitals 
evaluated the adherence to these efforts and the effect of prevention 
activities on HAI rates.  A majority had identified barriers to 
adherence and there was a wide range of educational and other 
interventions being conducted to improve effectiveness and increase 
performance. 
ii Reporting - In their recommendations, the Expert Panel supported 
the use of the Centers for Disease Control and Prevention’s (CDC) 
National Healthcare Safety Network (NHSN) for the collection and 
transmission of data and identified 10 outcome and 3 process 
measures for reporting and analysis.  They recommended 3 outcome 
measures for public reporting, 4 outcome and 3 process measures be 
reported to the BLC for evaluation before public reporting (but with 
the plan for public release in the future) and 3 outcome measures be 
monitored internally within healthcare facilities until more 
satisfactory standard definitions and/or metrics are established for 
reporting.  In April of 2009, the first preliminary public report, based 
on the first four months of data collection was released by the 
MDPH.  This report presented central line associated blood stream 
infection (CLABSI) rates by type of ICU, preliminary deep surgical 
site infection (SSI) rates for hip and knee arthroplasty (insufficient 
period of follow-up) and experience with the implementation of 
NHSN (with no pilot period). 
iii Multi-drug resistant organisms (MDRO) - As an initial step in the 
surveillance and control of multi-drug resistant organisms, the 
Expert Panel recommended a point prevalence survey of MRSA 
infections and colonization in ICU patients.  This survey was 
performed in September 2008.  A second point prevalence survey 
was recommended by the TAG to enhance understanding of these 
results, and this was completed in September 2009. 
iv Race and ethnicity - Understanding and preventing racial and ethnic 
disparities in healthcare is a high priority.  Beginning January 1, 
2009, all Massachusetts acute care hospitals were required to submit 
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data on race and ethnicity using “optional” NHSN fields and 
Massachusetts’ expanded ethnicity codes.  
 
B. Program Principles - The Massachusetts Statewide Infection Prevention and Control 
Program embarked on a comprehensive and thoughtful process to address infection 
prevention, public reporting and improvement initiatives.  The following principles 
reflect the broad-based approach to addressing the issue of HAI in Massachusetts. 
 
1. HAIs are recognized as an indicator of patient safety.  
2. The prevention of HAI is a leadership, organizational and management priority. 
3. Activities are based on current standards of practice and research, published 
guidelines, accreditation and regulatory requirements and related legislation. 
4. Targets and metrics are consistent with those identified by national organizations 
including CDC, the National Quality Forum (NQF), the Society for Healthcare 
Epidemiology of America (SHEA), the Association of Practitioners in Infection 
Control and Epidemiology (APIC) and the Infectious Diseases Society of America 
(IDSA).  
5. Commitment to prevention of all avoidable infections through culture change and 
proven quality improvement models. 
6. Selection of priority best practices for monitored application in healthcare facilities, 
with prioritization of interventions over 5 years for maximal impact on morbidity and 
mortality. 
7. Effective partnerships and breakthrough collaboratives that utilize integrated 
approaches for improvement.  
8. Promotion of transparency to motivate accountability and performance improvement 
and to provide consumers with information to make informed health decisions.  
9. Building capacity in an ongoing fashion 
10. Public engagement 
11. Sustainability – The prevention of HAI is a prioritized MDPH initiative. 
12. Learning from experience including the effective and timely analysis of initiatives to 
accelerate program improvement.   
 
C. Leadership and Technical Advisory Group  
 
1. Leadership Group  
a. Integration and coordination of the Division of Health Care Quality 
(DHCQ), Betsy Lehman Center for Patient Safety and Medical Error 
Reduction (BLC), and the Bureau of Infectious Diseases Prevention, 
Response and Services (BID) staff. 
b. The HAI Program Leadership Group consists of the Director and Deputy 
Director of the Bureau of Health Care Safety and Quality (BHCSQ, the 
Bureau containing DHCQ), the HAI program manager of the DHCQ, the 
program infection preventionists (2), the lead hospital surveyors (2), the 
Director of the Betsy Lehman Center, the program epidemiologists (2), the 
State Epidemiologist, the HAI Prevention Plan Coordinator and the project 
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manager of the primary contractor, JSI Research and Training Institute, 
Inc. (JSI). 
 
2. In response to the requirements of the HAI prevention funding awarded as part of the 
American Recovery and Reinvestment Act of 2009 (ARRA), a State HAI Prevention 
Coordinator position has been designated and was filled by September, 2009.  
 
3. Role Definitions  
a. Bureau of Health Care Safety and Quality (BHCSQ) - fiscal oversight of 
the HAI Program and supervision of the infection preventionists, and 
regulatory and technical personnel. 
b. Betsy Lehman Center for Patient Safety and Medical Error Reduction 
(BLC) - convening of expertise around best practices and research 
questions, and as a repository of pilot study data. 
c. Healthcare Associated Infection (HAI) Program - under the leadership of 
the plan coordinator, direction of the program and adherence to the plan. 
d. Bureau of Infectious Diseases (BID) - technical support for infection 
prevention recommendations, policies, and epidemiology of HAIs. 
e. JSI Research & Training Institute, Inc., (JSI) - major contractor providing 
technical support to all program components and operations, and 
management of sub-contracts.   
f. Technical Advisory Group (TAG) 
1) The TAG consists of hospital epidemiologists, infection 
preventionists, other clinicians, consumers, advocates, academics, 
and representatives from state agencies, professional organizations 
and trade organizations. 
2) The TAG advises the MDPH on all issues related to HAI and 
prevention, the results of reports and surveys, the application of 
surveillance and control methods and the presentation of the results 
to healthcare providers and the public. 
3) A full listing of TAG members and affiliations can be found in 
Attachment 1.   
 
4. Partnerships  
a. State Agencies  
1) Massachusetts Department of Public Health 
2) Betsy Lehman Center for Patient Safety and Medical Error 
Reduction 
3) Massachusetts Board of Registration in Medicine 
4) MassHealth (Medicaid agency) 
b. Trade organizations (hospital association, long term care, etc.) 
1) Massachusetts Hospital Association (MHA) 
2) Massachusetts Senior Care Association  
3) Massachusetts League of Community Health Centers 
4) End Stage Renal Disease Network of New England 
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c. Professional societies (physicians, nurses, nurse executives, specialty 
nurses, etc.)  
1) Association of Practitioners in Infection Control and Epidemiology 
2) Society for Healthcare Epidemiology of America 
3) Massachusetts Infectious Diseases Society 
4) Massachusetts Medical Society 
5) Massachusetts Nurses Association 
6) Infusion Nurses Society 
d. Consumer groups   
1) Massachusetts Coalition for the Prevention of Medical Errors 
2) Medically Induced Trauma Support Services 
3) Health Care for All 
e. Other   
1) Massachusetts Association of Health Plans 
2) MassPro (the Massachusetts CMS Quality Improvement 
Organization (QIO)) 
3) All four Massachusetts medical schools 
4) Eight specialty, tertiary care and community hospitals  
 
D. Completed and Ongoing Activities 
 
1. Designation of Coordinator - In line with Activity A of the Healthcare Associated 
Infections: Building and Sustaining State Programs to Prevent Healthcare Associated 
Infections section of the Epidemiology and Laboratory Capacity Cooperative 
Agreement, MDPH has designated a coordinator of the HAI Prevention and Control 
Plan. 
 
2. Infection Prevention Learning Collaboratives 
a. From July 2007 through June 2009, the Massachusetts Coalition for the 
Prevention of Medical Errors (the Coalition) 
http://macoalition.org/education.shtml provided educational programming 
and practice improvement coaching in collaboration with the MDPH and 
the Massachusetts Hospital Association (MHA), engaging hospital senior 
leadership and active participation of infection prevention and quality 
improvement staff.  Activities included the following: 
1) Seven statewide conferences and thirteen audio conferences 
focusing on cutting edge infection prevention and quality 
improvement strategies.  All hospitals participated in one or more 
of these programs. 
2) Six workshops and two conference calls to facilitate senior 
leadership engagement.  As a result of this engagement, senior 
leaders from all hospitals signed a letter of commitment 
prioritizing infection prevention for their facility. 
3) Maintenance of an active web site to share information. 
4) Creation of an active infection prevention listserve with 
approximately 300 members. 
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5) Production and dissemination of a compendium of 34 successful 
prevention projects reported by 24 hospitals. 
6) MDPH has contracted with the Coalition to extend and 
complement previous efforts to prevent HAIs. The Coalition will 
conduct two collaborative initiatives targeting reductions in central 
line associated blood stream infections (CLABSI), and multi-drug 
resistant organisms (MDROs), and will be guided in this work by 
the HAI TAG.    
 
3. Validation - Validation of data collected in an HAI reporting system is critical for the 
interpretation of results and the credibility of the system.  Validation protocols 
(details in further sections) will be developed, piloted and fully implemented.  
a. The goal of the validation plan is to verify the completeness and accuracy 
of reporting for CLABSI in ICUs, surgical site infections (SSI) for knee 
and hip arthroplasty, hysterectomy, and coronary artery bypass graft 
(CABG) procedures.  
b. In 2010, the HAI program epidemiologists, the department’s infection 
preventionists and contractors of the MDPH will pilot these protocols, 
reporting outcomes to the TAG. 
c. In consultation with the TAG, the application of validation protocols will 
be evaluated and potentially refined in late 2010, and applied to all acute 
care facilities in two steps, with 36 sites by December 2010 and all sites 
by December 2011. 
d. The data validation and verification protocols will be essential ongoing 
components of the HAI program.    
 
4. Expansion to Additional Sites - The health reform legislation and the HCQCC have 
mandates for expanding HAI prevention efforts across the full spectrum of health 
care delivery.  The Infection Prevention Work Group of the Patient Safety Sub-
Committee of the HCQCC has investigated best practices and reporting metrics for a 
number of care sites and agencies, engaging experts in each area of healthcare to 
contribute to an understanding of the care setting, the challenges faced in regard to 
infection prevention and best practices that have been identified. 
a. Ambulatory surgery - Best practices are being identified and metrics are 
being determined for ambulatory surgical centers (ASCs).  
1) In 2008, regulations were promulgated requiring free-standing 
ASCs to report infections through NHSN and infection control 
process measures according to guidelines presently under 
development. 
2) By July 2010, all free standing ASCs will be enrolled in NHSN. 
3) By December 31, 2011, a report of selected measures will be 
posted for public access.  
4) Surveyors will utilize the certification standards being developed 
by CMS when assessing these sites. 
b. Dialysis units – Best practices and potential reporting metrics are being 
identified for free-standing dialysis centers.   
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1) Measures for the reporting of HAIs including but not limited to 
bloodstream infections, will be established through a consultative 
process including the TAG and experts in dialysis care and 
infections in dialysis patients. 
2) Operators of dialysis units will be encouraged to participate in 
performance improvement collaboratives, such as that operated by 
the CDC/Delmarva Foundation Partnership or equivalent. 
3) In 2012, regulations for infection prevention and public reporting 
of quality measures, including HAI will be promulgated for 
dialysis units. 
4) By December 31, 2012, all free-standing dialysis units will be 
required to have in place reporting procedures specified by MDPH 
for the reporting of identified quality measures.   
c. Extended care -  inclusive of long-term care, rehabilitation hospitals and 
long-term/acute facilities 
1) A task group consisting of infection preventionists from extended 
and acute care facilities, experts in the area of extended care and 
geriatrics, and representatives of the extended care industry have 
reviewed potential metrics to monitor and report in these settings 
including influenza immunization of staff and residents. 
2) Metrics under consideration for recommendation to the HCQCC 
include indwelling urinary catheter days, immunization of staff and 
residents against influenza and hospitalization for infection. 
3) Surveys will be conducted in 2010 to assess the feasibility of these 
measures and a “needs assessment” will be used to evaluate the 
educational and technical requirements for future implementation.  
Data currently collected will provide baseline information for rates 
of infection, urinary catheterization and immunization, and will 
provide direction on the necessity of capturing additional HAI 
related information.  
4) The utility of NHSN for these facilities will be evaluated.  
5) Metrics will be established by July 2011. 
6) There will be ongoing evaluation of the performance of the metrics 
with adjustments made as needed, in consultation with the TAG. 
d. Infusion therapy centers  
1) In 2010, MDPH will continue the collaboration established with 
the Infusion Nurse’s Society and additional stakeholders in the 
evaluation of infection prevention in infusion therapy centers and 
to provide direction on the implementation of evidence based 
guidelines.  
e. Home care and hospice  
1) In 2011, MDPH will convene a task group to assess the current 
status of infection prevention in home care and hospice programs 
and to provide consultation on plans for assuring application of 
best practices and the potential for reporting measures of infection. 
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f. Primary care facilities  
1) The Healthcare Quality and Cost Council will require all settings 
in which patient care is delivered to establish a Patient Safety 
Program by 2012.  MDPH will continue to participate in this 
process to ensure infection prevention is identified as a core 
component.  
 
E. Program Targets and Best Practices  
 
1. Initial Prevention Targets  
a. Central line associated blood stream infections (CLABSI) in intensive care 
units (ICU) - 50% rate reduction by 2014 as compared to the 
Massachusetts rate identified in 2009. 
b. Surgical site infections (SSIs) - 25% rate reduction in deep incisional and 
organ space infections complicating hip and knee replacements, 
hysterectomies and coronary artery bypass graft (CABG) procedures by 
2014 as compared to the Massachusetts rates identified in 2009.  
c. Ventilator associated pneumonia (VAP) - 95% compliance with 
established VAP prevention program in place (self-measurement, justified 
program components - “bundle” or equivalent) by 2012. 
d. Multi-drug resistant organisms MDRO, Methicillin-resistant 
Staphylococcus aureus (MRSA) - 50% reduction in invasive MRSA cases 
associated with healthcare. 
e. Clostridium difficile - 30% reduction in C. difficile infection per 1000 
hospital discharges by 2014 as compared to the infections coded in 
hospital discharges in 2008. 
f. Selection of further targets and their implementation. The TAG will work 
with MDPH to identify new and enhanced prevention goals by mid-2012.   
 
2. Review and Update of Expert Panel Recommendations 
a. The TAG, with consultation of outside experts, will provide an ongoing 
review of current best practices and developments in the field of infection 
prevention. 
b. An annual review of priority targeted interventions and measures will be 
completed with members of the TAG.  Order of priority of review:  
1) 2010  -  Catheter Associated Urinary Tract Infection (CAUTI), 
Multidrug-resistant organism (MDRO), Clostridium difficile 
associated disease (CDAD) 
2) 2011  -  CLABSI, Surgical Site Infection (SSI)  
3) 2012  -  Ventilator associated pneumonia (VAP), MDRO, CDAD 
4) Thereafter, as indicated by ongoing review of the evidence-base 
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3. Validation of Reported Measures  
a. A data quality assurance and validation system is critical to the success of 
the statewide program.  To ensure the accuracy and completeness of the 
individual facility rates and the overall metrics MDPH is working with its 
technical contractor to develop and implement methods of data validation, 
including, but not limited to:  
1) Laboratory report reviews 
i. Laboratory results indicating positive blood cultures in ICU 
patients will be obtained from acute care hospitals.  These 
data will be compared to trends in reported CLABSIs.  
Outliers or facilities with CLABSI reports appearing to be 
discordant with numbers of positive blood cultures will be 
investigated for unreported bacteremias. 
ii. Positive blood culture reports will also result in medical 
record reviews by program staff to assess relatedness to 
central line utilization or surgical procedures. 
2) Medical record reviews 
i. Medical record reviews designed as a component of the 
validation protocols developed in 2010 will be performed 
on a sample of reported cases to rule out “false positives”.   
3) Review of clinical laboratory and discharge data  
i. Laboratory reports obtained through Electronic Laboratory 
Reporting (ELR), the Hospital Discharge Data Set (HDDS) 
and the Centers for Medicare and Medicaid Services 
(CMS) performance measures (such as the Surgical Care 
Improvement Project (SCIP) measures) will be analyzed as 
sources of relevant data on progress toward goals as well as 
for validation of reported measures by December 2011.   
4) Data review of procedures and central venous catheter days to 
assess accuracy of denominator data 
i. Volume of procedures and numbers of catheter days will be 
monitored over time for consistency and will be compared 
to data from the HDDS. 
ii. Outlier analysis and follow-up will be used for validation.   
5) Emergency department records  
i. Massachusetts collects emergency department visit data 
and short stay data at acute care hospitals.  These data sets 
will be used to identify patients re-admitted with potential 
wound infections and will be compared to reported 
occurrences.   
6) Algorithms for checks of internal data consistency will be 
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4. Ongoing Initiative  
a. Immunization against influenza - achieving at least 90% immunization of 
healthcare workers against influenza 
1) In 2008-09, MDPH required acute care facilities to report their 
success in providing influenza vaccine to their employees (defined 
by payroll).   
2) In September 2009, MDPH required acute care facilities, licensed 
clinics and extended care facilities (extended care facilities had 
been required previously to provide seasonal influenza vaccine) to 
provide both seasonal and pandemic H1N1 influenza vaccine to all 
personnel (broadly defined to include contractors, volunteers and 
students) free of charge.  Due to the newness of the requirements 
and difficulties associated with vaccine supply, only the acute care 
facilities were required to report immunization levels in 2010.  The 
deadline for submission of these data is April 15, 2010.   
3) In 2011, MDPH will require extended care facilities to report 
influenza immunization rates for all personnel.  
4) In 2012, MDPH will require licensed clinics to report staff 
immunization rates for all personnel.  
 
5. Communication Plan  
a. Consistent with the principles of transparency and public engagement, the 
HAI Program’s ultimate goal for surveillance and reporting is to provide 
full public access to data on reported outcomes and process measures that 
are required by the MDPH.  Format will be determined by MDPH with the 
advice of the TAG (see below).  All meetings of the TAG are open 
meetings and minutes and reports are public documents.  
b. Periodic presentations are provided for the Massachusetts Public Health 
Council, which constitutes the legal entity of MDPH under the 
Commissioner who serves as chair with authority to approve regulations.  
Promulgation of regulations and regulatory amendments are subject to 
public comment and review and approval of the Public Health Council.      
 
6. Agency and Provider Accountability  
a. Healthcare facilities will be held accountable under regulations of the 
MDPH Division of Healthcare Quality for full compliance with:  
1) Implementation of best practices, including recommendations of 
the Expert Panel, any revisions in these guidelines as indicated 
above, the Healthcare Infection Control Practices Advisory 
Committee (HICPAC) and requirements of CMS. 
2) Maintenance of participation in NHSN and timely and accurate 
completion of data collection and entry. 
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F. Surveillance and Reporting 
 
1. Utilization of NHSN and Other Mechanisms of Reporting 
a. Expectations  
1) All licensed acute care hospitals are currently enrolled in and 
utilizing NHSN effectively and reliably. 
2) By July 1, 2010, all ambulatory surgical centers will be enrolled in 
NHSN and proficient in the use of the appropriate NHSN modules 
addressing quality metrics identified by MDPH for reporting. 
3) By December 31, 2012, all dialysis units will have established 
policies and procedures to assure the transmission of reports of 
blood stream and/or other infections associated with dialysis at 
transition of care to acute care or extended health care facilities.    
4) By July 1, 2010, all extended care facilities will be capable of 
reporting quality metrics identified by MDPH in a form and 
manner determined by MDPH. 
5) In the event of the development of appropriate and feasible 
modules for NHSN reporting of metrics from extended care 
facilities, NHSN may be adopted by these facilities for reporting. 
6) By December 31, 2010, all clinical laboratories licensed to provide 
diagnostic services in the Commonwealth will be reporting data 
required by MDPH regulations through the established electronic 
laboratory reporting (ELR) system. 
b. Health Care Facility Support 
1) NHSN provides interactive distance learning and is available for 
individualized consultation at nhsn@cdc.gov 
2) JSI maintains a dedicated e-mail address (haihelp@jsi.com) and 
telephone number (617-385-3992) for submission of questions 
related to NHSN and surveillance of HAI.  Technical assistance 
will be provided by contractor through December 31, 2011.  
3) Staff epidemiologists have developed a quality assurance protocol 
to monitor and provide feedback to hospitals on data reported to 
NHSN.   
4) MDPH staff provides additional support on the reporting 
requirements on a case-by-case basis.   
c. Evaluation  
1) Reviews of data for internal consistency and completeness of 
meeting NHSN requirements for data entry. 
2) Application of data validation algorithms. 
3) Validation procedures, as described above. 
4) Periodic review, as above. 
d. Infrastructure  
1) Electronic laboratory reporting (ELR) 
ii. HL7 standards 
iii. LOINC, SNOMED standards 
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iv. All clinical laboratories licensed to operate in 
Massachusetts will be required to participate in ELR by 
December 31, 2010.  
2) Massachusetts Virtual Epidemiologic Network (MAVEN) 
i. Web-based, disease surveillance and case management 
application with ELR interface.   
ii. Exploration of interoperability with NHSN during 2010-
2011.  
iii. The developed “outbreak module” that has been created in 
MAVEN offers facilities a web-based outbreak 
management tool that can interface with MDPH.  It is 
currently being piloted at one hospital.  If its utility to 
infection prevention programs is established, it will be 
provided free-of-charge to hospitals in 2011. 
 
2. Procedure for Determining Level of Reporting for HAI Related Process and 
Outcome Measures (public, agency, internal )  
a. Default reporting will be to the public 
b. Reporting to the BLC of any metrics during a pilot phase or when there is 
uncertainty about the reliability of data collection or basis of comparison 
of facilities (case mix differences, service provided, level of care, etc.). 
c. Internal reporting, within the institution for tracking performance and 
results of quality improvement activities not for public dissemination. 
Measures where standardization is uncertain or are relevant to specialized 
services provided may be recommended for internal reporting.  These 
measures must be in a format available for review by MDPH.  
 
3. Public Reporting of HAI Related Process and Outcome Measures  
a. Communication Plan – All public reporting will be accomplished:   
1) Through periodic written reports. 
2) Through a website that is part of or linked to the existing HCQCQ 
site: “My Health Care Options”.  
3) By July 1, 2010, the following data, related to reporting 
requirements for acute care hospitals will be available on the 
website:  
i. SSI resulting after primary hip or knee arthroplasty, by 
hospital, July 1, 2008 - June 30, 2009. 
ii. CLABSI (Criterion 1) in ICU patients, by hospital, July 1, 
2008 - June 30, 2009. 
iii. CLABSI (Criteria 1, 2 and 3) in ICU patients, in aggregate, 
by ICU type. 
iv. SSI resulting from abdominal and vaginal hysterectomy, in 
aggregate, by hospital type, July 1, 2008 - June 30, 2009. 
v. SSI resulting from CABG, in aggregate. 
vi. Point prevalence surveys of MRSA in ICUs, September 
2008 and September 2009, in aggregate. 
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vii. Influenza vaccination of employees, 2008 - 2009, in 
aggregate. 
viii. Influenza vaccination of health care personnel, 2009 - 
2010, by hospital. 
4) By July 1, 2011, reportable outcome and process measures for 
infection prevention in ambulatory surgical centers and long term 
care facilities will be added to the web site.  
5) Public reporting of HAI will utilize CDC recommended qualitative 
indicators, including standardized infection ratios (SIR).   
b. Reporting from non-acute healthcare facilities and agencies – enhanced 
surveillance  
1) Identification of measures for extended care, dialysis units, home 
care and hospice and other sites, as per above. 
2) Implementation 
i. Data systems will be identified as measures and capacities 
are established. 
3) Ongoing evaluation of validity, utility, transparency and public 
application. 
c. Multi-drug resistant organisms (MDRO) and Clostridium difficile 
1) Methicillin-resistant Staphylococcus aureus (MRSA) 
i. MDPH will continue and expand reporting of invasive 
MRSA infection, with implementation of electronic 
laboratory reporting from all licensed clinical laboratories 
by December 31, 2010. 
ii. Clinical laboratories will connect via ELR as per 
requirements that became effective as regulatory 
amendments in 2008 (105 CMR 300). 
iii. All laboratories will report isolates of MRSA obtained from 
blood cultures or from cultures of other normally sterile 
body fluids and sites. 
iv. By July 2011, MDPH will analyze these reports and 
calculate population-based rates of invasive MRSA 
infection using hospital proportion of hospital discharges to 
estimate proportion of Massachusetts population at risk. 
v. MDPH will explore methods to capture admission date 
with laboratory reports received through ELR in order to 
establish likelihood of laboratory results representing 
healthcare-acquired infections.  
a) If feasible, by July 2012, MDPH will analyze these 
laboratory results with respect to positive cultures 
collected before and after two days following date of 
admission.  
vi. By December 31, 2010, MDPH will publicly report 
population-based rates of invasive MRSA infection, in 
aggregate, statewide and by region, to establish a 
benchmark.   
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a) It will be noted that these rates will initially be inclusive 
of community-associated, as well as healthcare 
associated, infections. 
b) If feasible, per above, by December 31, 2012, MDPH 
will publicly report rates of healthcare-associated 
invasive MRSA infection (as defined above in terms of 
culture positivity after admission) by hospital. 
vii. MDPH will continue to encourage and accept submission 
of all clinical isolates of S. aureus potentially resistant to 
glycopeptide antibiotics such as vancomycin, as part of 
state and national surveillance for confirmed vancomycin 
resistance.     
viii. MRSA point prevalence surveys 
a) The results of the second MRSA point prevalence study 
in ICUs will be analyzed by February 2010. 
b) By July 2010, the results of the second point prevalence 
survey will be reviewed by the TAG and 
recommendations will be made as to the need or design 
of further studies or prevention measures.   
2) Antibiograms 
i. MDPH will continue to monitor aggregate antibiotic 
susceptibility reports from clinical laboratories for 
proportion of Staphylococcus aureus isolates that are non-
susceptible to oxacillin (MRSA). Currently, such 
“antibiograms” are submitted voluntarily, and laboratories 
will be encouraged to continue doing so.    
ii. By December 31, 2010, regulation will be promulgated to 
require all licensed clinical laboratories in Massachusetts to 
adhere to the Clinical and Laboratory Standards Institute 
(CLSI) guideline for standard reporting of antibiograms, as 
presented in Analysis and Prevention of Cumulative 
Antimicrobial Susceptibility Test Data; Approved 
Guideline - Third Edition (M39-A3), or as amended in 
further editions, and with consideration given to laboratory 
volume of specimens processed and results generated.  
iii. By December 31, 2010, regulation will be promulgated to 
require all licensed clinical laboratories in Massachusetts to 
submit institutional antibiograms for sequential 12 month 
periods (calendar, academic or fiscal year), with 
consideration given to laboratory culture volume and 
multiple sources of culture submission (outpatient versus 
inpatient).  
iv. MDPH will explore electronic means of transmission of 
antibiogram data or direct transmission of susceptibility test 
results.   
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v. MDPH will provide periodic public reports of trends in S. 
aureus susceptibility to oxacillin and other antimicrobial 
agents, based on antiobiogram analysis.  
3) Clostridium difficile 
i. MDPH will monitor C. difficile infection in hospitalized 
patients using the uniform Hospital Discharge Data Set 
(HDDS) and codes for C. difficile infection (ICD-9: 008.45; 
ICD-10: A04.7) in any field. 
ii. By December 2010, MDPH will provide a report on C. 
difficile infection in Massachusetts; trends, demographics, 
hospitalization type (primary or secondary diagnosis) and 
outcomes, using the HDDS and death certificate data. 
iii. By December 31, 2011, MDPH, in consultation with the 
TAG, will review available data and data sources on C. 
difficile infection and make a determination as to useful 
public reporting by facility or facility type. 
iv. By January 1, 2011, all clinical laboratories will report 
stool specimens positive for evidence of toxigenic C. 
difficile infection by ELR. 
vi. MDPH will explore methods to capture admission date 
with C. difficile laboratory reports received through ELR in 
order to establish likelihood they represent healthcare-
acquired infections.   
vii. In 2012, MDPH will evaluate the use of laboratory 
reporting of stool specimens positive for evidence of 
toxigenic C. difficile infection as a means of monitoring 
trends in C. difficile infection and as a surrogate for 
infection acquired in a healthcare facility (positive 48 hours 
or more hours after admission, with a negative or absent 
earlier result) versus community-acquired. 
4) Other MDROs 
i. Recognizing that MRSA infection accounts for a small 
proportion of all healthcare-associated infections, MDPH 
will put into place monitoring of antibiograms for trends in 
other organisms of concern associated with healthcare-
associated infection, including, but not limited to, gram-
negative bacilli in general, extended-spectrum beta-
lactamase (ESBL) producing organisms and 
carbapenemase-producing organisms. 
ii. MDPH will co-sponsor conferences on infections due to 
extended-spectrum beta-lactamase-producing organisms, 
carbapenemase-producing organisms and other gram-
negative MDROs in the spring and fall of 2010. 
iii. By December 31, 2010, MDPH will present a report to the 
TAG on occurrence and trends in MDROs of concern to 
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inform and guide consideration of further surveillance 
activities and prevention initiatives.    
5) Response to MDRO surveillance findings outside of expected 
i. By July 1, 2011, MDPH, in consultation with the TAG, will 
develop guidelines for the interpretation of facility/agency 
specific surveillance indicators of prevalence or incidence 
of MDROs that will trigger surveys and interventions to 
establish cause and recommend evidence-based prevention 
interventions. 
 
4. Evaluation of Validity, Utility, Transparency and Public Application of Reported 
Measures 
a. Analysis  
1) JSI will develop and implement protocols using shared products of 
CDC and other states to validate completeness and accuracy of 
reporting.  These protocols will be piloted in 3 acute care facilities 
in early 2010 and then applied to the 36 acute care facilities by 
December 31, 2010.  All acute care facilities will have these 
validation methods applied by December 31, 2011. 
2) In 2010, JSI and MDPH will explore the use of the hospital 
discharge data set, CMS performance measures and ELR data for 
use in validation of measures reported by acute care hospitals. 
b. Provider input  
1) MDPH infection preventionists will collect programmatic 
suggestions from facility-based providers and others as part of 
their routine and complaint generated visits.  Periodic surveys of 
providers will be performed to assess their opinions regarding 
surveillance and use of data.  
c. Public input  
1) Public input will be solicited on the accessibility and utility of data 
presented to the public. 
2) Utility and public application of the data reported by facilities will 
be measured by consumer satisfaction surveys, number of “hits” on 
the reporting web sites and surveys of how consumers use the 
reported information in making informed decisions. 
i. Consumer surveys will be conducted annually beginning in 
2011. 
ii. Web site visits will be monitored monthly. 
iii. Public feedback will be continuously solicited. 
d. CDC recommendations 
1) Evaluation and validation of mandatory reporting will be guided 
by protocols developed by CDC. 
e. Experience of other jurisdictions 
1) The shared experiences of other jurisdictions will be of great value 
in operations of the program and evaluation of parameters of 
success.  
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f. Process for selection of additional HAI process and outcome measures 
1) CDC and the United States Department of Health and Human 
Services (DHHS) guidance. 
2) Recommendations of the TAG. 
3) Identification of emerging HAI issues. 
4) Experience of other jurisdictions. 
 
G. Evaluation and Oversight 
 
1. Oversight  
a. Healthcare facilities will be held accountable under regulations of the 
MDPH Division of Healthcare Quality for full compliance with:  
1) Incorporation of review of compliance with HAI prevention and 
reporting requirements in routine and other surveys. 
2) Periodic review of HAI prevention and reporting efforts by MDPH 
infection preventionists. 
3) Review of NHSN data and other reports. 
b. Experience with review and oversight will guide ongoing improvement of 
processes and responses to serious breaches in infection control, suspect 
cases and clusters, and outbreaks. 
c. The formalization of infection prevention review and oversight will 
enhance the already well-established collaboration of DHCQ and BID in 
occurrence and outbreak investigation and follow-up. 
 
2. Efficacy of Acute Care Facility Programs  
a. Process measures  
1) MDPH infection preventionists and DHCQ surveyors will review 
facility adherence to best practice process measures, including but 
not limited to the central line bundle and VAP prevention 
processes.  Feedback will be given to facilities. 
b. Outcomes  
1) Outliers at one or two standard deviations of standardized infection 
ratio (SIR) of reported outcome measures will be identified for 
review for accuracy of surveillance and reporting, as well as 
application of prevention measures. 
c. Programmatic adequacy  
1) Routine and complaint driven surveys will assess application of 
best practices, effectiveness of multidisciplinary teams (as 
evidenced by minutes of meetings, responses to out of range 
indicators, quality improvement initiatives), and staffing.   
 
3. Provider Behavior and Behavior Change - All licensed healthcare facilities in 
Massachusetts are required by regulation or under deemed status to have an infection 
prevention and control program.  As above, facilities are currently required or will be 
required to report quality indicators related to infection prevention, including process 
and outcome measures. 
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a. Performance  
1) Process and outcome measures submitted through NHSN and 
directly to the MDPH will be monitored for outliers, with both 
positive and negative deviation from the mean. 
i. By December 2010, MDPH in consultation with the TAG 
will establish parameters for identification of outliers for 
specific process and outcome measures. 
ii. Using these parameters, MDPH will identify positive and 
negative outliers and query them for possible explanations 
of their reports (data error, artifact, successful or failed 
policies or procedures). 
iii. MDPH infection preventionists will follow-up with site 
visits and surveys, as necessary.    
b. Interventions  
1) Negative outliers, as defined by the parameters set as above, will 
be queried as to cause. 
2) If response suggests a true outlier condition, a formal survey will 
result, with a plan of correction being required. 
3) The plan of correction will be in place until the facility can 
successfully demonstrate improved performance on the measure in 
question.  
4) Analysis of reported data will be used to target and promote 
focused infection prevention programs.  
 
H. Education and Training 
 
1. Promotion of Best Practices - A fundamental commitment is made to the promotion 
of the best, evidence-based practices that have been demonstrated to reduce HAI.  In 
order to accomplish this, the Statewide Infection Prevention program will: 
a. Provide clear expectation of hospital compliance with best practices 
consistent with the recommendations of the Expert Panel, HICPAC and 
other authoritative sources. 
b. Routinely communicate updates and revisions to guidance on infection 
best practices to healthcare facilities and additional stakeholders.  
c. Promote best practices through statewide prevention collaboratives (see 
below). 
d. The Statewide Infection Prevention Program shall solicit feedback on 
recommended practices, as well as monitor trends in outcome and process 
measures reported and maintained by the facilities relevant to the 
practices. 
  
2. Collaborative Learning - A major goal over the next two years will be to establish 
statewide collaboratives and communities of practice to build capacity in addressing 
HAI using evidence-based methods.  The focus will be on proven methods and 
assessment applying a general plan-do-study-act (PDSA) cycle approach. 
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a. The Massachusetts Coalition for the Prevention of Medical Errors, under 
contract with MDPH and working closely with the BLC, MHA, MassPro 
(the state CMS QIO) and the Eastern Massachusetts Health Initiative 
(Boston-area hospitals sharing best practices to reduce infections), will 
continue to provide support and facilitation for collaborative efforts in 
reducing HAIs. The approach will incorporate Positive Deviance change 
process to promote staff ownership combined with group exploration and 
idea generation through discovery and action dialogues, applying 
principles of adult and group learning in working sessions of the 
collaborative.  
b. Eliminating Central Line Associated Blood Stream Infections (CLABSI).  
Beginning in October 2009, the Coalition and the MHA will coordinate 
the participation of at least 10 hospital ICUs in the second cohort of the 
Initiative to Reduce Central Line Associated Blood Stream Infections 
based on the Michigan Keystone Initiative.  The program will include: 
1) Implementation of the Comprehensive Unit-Based Safety Program 
(CUSP) and other interventions to reduce CLABSI, with focus on 
creating a culture of safety and the use of checklists, utilizing face-
to-face learning sessions and monthly coaching calls for ICU staff, 
and monitoring rates before and after the interventions.  CUSP 
learning sessions, coaching calls, and data monitoring and review 
activities are scheduled for October 2009 through May 2011. 
2) Efforts will be made to replicate this program in all ICUs in acute 
care hospitals by December 31, 2011, using the local capacity 
generated by participation in the CUSP.   
c. Multi-Drug Resistant Organisms - The Coalition, under contract with 
MDPH, will begin a second HAI prevention collaborative applying the 
Positive Deviance approach, combined with conventional quality 
improvement approaches, including tests of change (PDSA cycles) to 
address a range of MDROs, including, but not limited to, MRSA, 
Clostridium difficile and vancomycin-resistant enterococci (VRE). 
1) The Coalition will collaborate with MassPRO to share best 
practices identified during the MRSA prevention efforts under the 
CMS 9th Scope of Work. 
2) The Coalition will continue the collaboration with the Eastern 
Massachusetts Health Initiative in ongoing and extended efforts to 
reduce infections related to MDROs. 
3) The Coalition and MDPH will continue to seek input and advice 
from the TAG on best practices and evidence-based approaches.   
4) Hospital teams will participate in learning groups, face-to-face 
sessions, coaching calls and sharing of experiences (June, 2010 
through October, 2011). 
5) The MHA will continue to engage senior hospital leadership in 
these efforts. 
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6) On-going review of the collaborative process will lead to the 
identification of sustainable programs to maintain reductions in 
infections related to MDROs. 
7) By December 2011, BLC and MDPH will take this information 
and establish standards for policies and procedures to reduce 
MDROs. 
8) Established standards and outcome measures will be monitored 
through 2012 by surveys and reports of MDROs. 
9) Evaluation of results of MDRO infection reduction initiatives will 
be reviewed by the TAG at the end of 2010 for the purposes of 
consideration of new or modified recommendations.  
d. Massachusetts Neonatal Quality Improvement Collaborative – Mass 
NeoQIC is an existing collaborative of neonatologists from all 10 level 3 
neonatal intensive care units (NICUs) in Massachusetts.  They have 
approached MDPH to work with them in their efforts to reduce 
preventable infections.  They meet 2-3 times per year and are in the 
process of exploring formal incorporation.  Massachusetts level 3 NICUs 
have joined the Vermont Oxford Network (VON) and have reached out to 
colleagues in neighboring states, including the New York Regional 
Perinatal Centers for sharing of best practices and data.  The member 
NeoQIC NICUs are currently tracking the VON infection indicators, as 
well as reporting CLABSIs to MDPH through NHSN.  They have 
executed formal agreements to share deidentified data among member 
NICUs. 
1) MDPH recognizes NeoQIC as a quality improvement collaborative 
and will partner with NeoQIC in the area of infection prevention. 
2) MDPH staff will work with MassNeoQIC in identification of best 
practices, reporting of NICU measures of infection and utilization 
of data for quality improvement. 
3) MDPH will use NeoQIC as an additional source of consultation 
related to infection prevention issues in neonatal intensive care.   
 
3. Solicitation of Best Practices and Sharing of Successful Program Elements. 
a. In addition to formal collaboratives, the BLC, the MDPH and contractors 
will create opportunities for the sharing of best practices across the 
spectrum of health care delivery, including hospitals, outpatient care sites, 
ASCs, dialysis units, home care, etc.  This will be done through annual 
and more frequent conferences, surveys and visits by MDPH infection 
preventionists and Division of Health Care Quality staff.  
b. The BLC and MDPH will utilize the TAG in an advisory capacity and 
convene work groups on specific topics and issues.  The goal will be to 
create “communities of practice” within and across disciplines. 
 
4. Standards for Competence and Practices 
a. In 2010, MDPH will engage the TAG in further defining best practices for 
training and certification of professionals in HAI prevention. 
Page 21 of 25 
Massachusetts Healthcare-Associated Infection Plan December 31, 2009 
b. MDPH will consult with internal and external expertise in regard to 
establishing requirements for education, training and certification of 
healthcare professionals in HAI prevention.   
 
5. Health Department Training 
a. MDPH staff will participate in conferences and training opportunities 
presented by CDC and other agencies, as well as participate in educational 
programs provided by partners in HAI prevention, including JSI and sub-
contractors. 
1) MDPH and JSI staff will continue to participate in monthly NHSN 
state users calls. 
2) MDPH staff will participate in monthly Council of State and 
Territorial Epidemiologists (CSTE) calls.  
 
6. Healthcare Facility Staff Training    
a. JSI will provide four teleconference training sessions for facilities utilizing 
NHSN. Topics will focus on data cleaning issues, updates to NHSN 
modules, NHSN skills, and analysis of data.  
b. NHSN training will be ongoing for current and new users. 
c. Working with professional organizations and academic partners, MDPH 
will offer or co-sponsor conferences and other opportunities in infection 
prevention education. 
d. As new facilities, such as ASCs and extended care facilities begin 
reporting process and outcome measures, MDPH will provide technical 
assistance in the use of NHSN and other data systems to be used for 
monitoring and reporting. 
e. Training on NHSN and applicable NHSN modules will be offered to ASC 
staff in 2010. 
f. As metrics are developed for extended care facilities prior to June 30, 
2010, appropriate face-to-face and teleconference trainings will be 
designed and offered on data systems, surveillance definitions and 
reporting. 
g. By July 2012, MDPH will promulgate regulations to require all licensed 
healthcare facilities to provide annual infection prevention training for all 
staff, appropriate to their job function, and suitable to the work site, 
including but not limited to hand hygiene, newly identified best practices, 
cleaning and disinfection, and emerging infections.  Details of these 
regulations will be determined through the established regulatory 
development and promulgation process. 
 
I. Public Engagement and Education  
1. Communication Plan - The Statewide Infection Prevention Program will issue 
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2. Assuring Transparency 
a. All reports of measures mandated to be reportable will be posted on the 
web sites indicated above.  
b. All meetings of the TAG shall be open and all minutes and reports shall be 
treated as public documents, unless the TAG is acting in a capacity of 
consultation or review with the BLC under its confidentiality protection.  
 
3. Evaluating Penetration and Utilization of Reported HAI Information  
a. The Statewide Infection Prevention Program will assess use of published 
information by the public through: 
1) Review of consumer queries or complaints addressed to MDPH. 
2) Surveys of consumer knowledge, attitudes and behaviors related to 
the reported data.  
3) Questions in the 2011 Behavioral Risk Factor Surveillance System 
(BRFSS) addressing awareness of HAI, knowledge of programs to 
address HAI, and understanding and use of comparative data 
provided by the Statewide Infection Prevention Program. 
4) Feedback provided by organizational partners.  
 
4. Targeted Information and Educational Campaign 
a. The Statewide Infection Prevention Program will continue to work with 
the Partnership for Healthcare Excellence and additional consumer 
advocacy groups on fact sheets, guides and public information efforts to 
address: 
1) Hand hygiene 
2) Consumer participation and role in reducing HAI 
3) Prudent use of antibiotics 
4) Effective use of available sources of information to make health 
care decisions 
b. 2009 amendments to hospital licensure require hospitals to establish 
Patient and Family Advisory Councils.  The Statewide Infection 
Prevention Program will explore the potential for increased patient and 
family participation through collaboration with these new entities. 
 
J. Ongoing Economic Analysis 
1. In addition to the CMS Medicare non-payment of hospital-acquired conditions 
related to infection prevention (catheter-associated urinary tract infection, vascular 
catheter-associated infection, mediastinitis after coronary artery bypass grafting and 
surgical site infections following certain orthopedic procedures and bariatric 
surgery), the Massachusetts Cost Containment, Transparency and Efficiency Act of 
2008 (Chapter 305 of the Acts of 2008) required reporting of healthcare-associated 
infections (and other serious adverse events defined by the National Quality Forum) 
with a provision for non-payment of claims for preventable HAIs and other SREs. 
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2. In 2010, MDPH will seek academic partners to develop a method of using 
information collected by CMS and the HCQCC on claims denied based on 
preventable HAI and SREs to assess economic impact of these events. 
 
3. In 2011, MDPH will explore further methods of assessing the economic impact of 
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K. Appendices  
1. Prevention and Control of Healthcare-Associated Infections in Massachusetts,   Part 
1: Final Recommendations of the Expert Panel at: 
http://www.mass.gov/Eeohhs2/docs/dph/patient_safety/haipcp_final_report_pt1.pdf.  
2. Prevention and Control of Healthcare-Associated Infections in Massachusetts. Part 2: 
Findings from Complementary Research Activities at: 
http://www.mass.gov/Eeohhs2/docs/dph/patient_safety/haipcp_final_report_pt2.pdf. 
3. Technical Advisory Group Membership (attachment 1)  
4. Preliminary surveillance report at: 
http://www.mass.gov/Eeohhs2/docs/dph/quality/healthcare/hai_prelim_report.pdf. 
5. Template for State Healthcare Associated Infections Plan (attachment 2) 
6. Gantt chart of selected activities (attachment 3) 
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